Zai Lab's revenue growth has decelerated sharply from 65.7% in 2024Q4 to -3.3% in 2026Q2, while gross margins compressed from 64.9% to 54.7% over the same period, indicating eroding pricing power and a loss of commercial momentum. Operating losses remain eleva...
Price trend, volume and key moving averages
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 6, 2026 | -$0.46+32.3% vs -$0.68 | $106M+2.4% vs $104M |
Q2 2026 May 7, 2026 | -$0.46+12.6% vs -$0.53 | $100M-8.1% vs $108M |
Q1 2026 Feb 26, 2026 | -$0.46-4.5% vs -$0.44 | $128M+4.4% vs $122M |
Q4 2025 Nov 6, 2025 | -$0.33-17.9% vs -$0.28 | $116M-18.1% vs $142M |
Z.ai's shares rose after the company launched a new AI model that it claimed runs only on Chinese chips. It's the latest indication of China's efforts to ramp up homegrown computing capability.
ZLAB has grown from a Greater China licensing platform into a dual-engine biopharma. They have a growing proprietary global pipeline with KarXT and TIVDAK. And management expects product sales to stabilize during 2H2026. Zoci's SCLC and NEC activity looks promising, while their other partnered combo therapies could expand their indications across other treatments.
SHANGHAI & CAMBRIDGE, Mass. & AMSTERDAM--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) and argenx (Euronext & NASDAQ: ARGX), today announced positive topline results from the ALKIVIA Phase 3 study evaluating VYVGART® Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) in adults with autoimmune myositis. Study met its primary endpoint (p=0.0011) In the combined immune-mediated necrotizing myopathy (IMNM) and dermatomyositis (DM) population, patients treated with efgartigimod dem.
Zai Lab NASDAQ: ZLAB said its second-quarter net product revenue rose 11% sequentially to $105.8 million as the company continued to invest in a pipeline it expects to support a transition into a global biopharmaceutical business.
Benchmark ZLAB against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Zai Lab Limited (ZLAB)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $26.44 | $2.99B | -16.53 | 15.33% | -38.15% | -22.56% | — | |
| $18.45 | $3.41B | -11.53 | 64.04% | -7.21% | -8.7% | — | |
| $27.50 | $2.02B | -25.46 | 38.87% | -138685.11% | -222.5% | — | |
| $0.39 | $279.43M | -0.86 | 96.69% | -67.79% | -80.25% | — | |
| $26.39 | $3.32B | -8.02 | -4.26% | -386.32% | -87.98% | — | |
| $34.54 | $7.13B | -12.47 | — | -7585.86% | -69.59% | — |
Zai Lab Limited (ZLAB) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Zai Lab Limited (ZLAB) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 6, 2026·SEC
Jun 17, 2026·SEC
May 21, 2026·SEC
Get notified when ZLAB posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Zai Lab Limited (ZLAB) stock FAQ — growth, dividends, profitability & financials explained
Zai Lab Limited (ZLAB) reported $449.6M in revenue for fiscal year 2025.
Zai Lab Limited (ZLAB) grew revenue by 15.3% over the past year. This is strong growth.
Zai Lab Limited (ZLAB) reported a net loss of $188.2M for fiscal year 2025.
Zai Lab Limited (ZLAB) has a return on equity (ROE) of -22.6%. Negative ROE indicates the company is unprofitable.
Zai Lab Limited (ZLAB) had negative free cash flow of $144.5M in fiscal year 2025, likely due to heavy capital investments.
